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Erratum
Development of the International Thymic Malignancy Interest Group International Database: An Unprecedented Resource for the Study of a Rare Group 
of Tumors: Erratum
The article that appeared on page 1573 of the October 2014 issue of the Journal of Thoracic Oncology contained errors. The paragraph 
under the heading “Treatment” in the Results section should have appeared as follows:
TrEaTmEnT
The vast majority of submitted cases were treated at initial diagnosis with surgery as primary therapy (Fig. 2). Adjuvant radiotherapy was 
administered to 1664 patients (42%), and a minority of patients received neoadjuvant therapy, either chemotherapy (11%) or radiotherapy 
(2%). Less than 1% of cases received palliative chemotherapy (n = 27) or radiotherapy (n = 7) only.
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